Using Fluoroethyltyrosine FET PET Scan to Detect and Characterize Brain Tumors in Patients With Intracranial Neoplasms

What this Trial Is About

Researchers are evaluating how Fluoroethyltyrosine FET Positron Emission Tomography PET scans can help detect and characterize brain tumors called intracranial neoplasms. The study focuses on distinguishing between treatment-related changes and tumor recurrence in patients with metastatic disease and gliomas, as well as differentiating between low-grade and high-grade gliomas. This observational study aims to improve understanding of tumor behavior and guide treatment decisions through imaging. Participants will receive a single FET PET scan lasting about 40 minutes after an injection of the FET drug given intravenously. Some adult participants may have up to two additional FET PET scans. The study includes two groups one with patients who have previously been treated but have suspected recurrence, and another with patients who are about to undergo biopsy or surgery before standard treatment. Adverse events during the scans will be recorded. During the study, participants will undergo the FET PET imaging procedure in an outpatient setting. Researchers will assess tumor-to-background ratios and the accuracy of tumor detection by comparing scan results to pathology or imaging follow-up over up to three years. Safety and tolerability of the scans will be monitored. Participation involves imaging visits and follow-up for outcomes related to tumor detection and clinical status.

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm